MX2023001556A - Anticuerpos que se dirigen a egfr y uso de los mismos. - Google Patents

Anticuerpos que se dirigen a egfr y uso de los mismos.

Info

Publication number
MX2023001556A
MX2023001556A MX2023001556A MX2023001556A MX2023001556A MX 2023001556 A MX2023001556 A MX 2023001556A MX 2023001556 A MX2023001556 A MX 2023001556A MX 2023001556 A MX2023001556 A MX 2023001556A MX 2023001556 A MX2023001556 A MX 2023001556A
Authority
MX
Mexico
Prior art keywords
proteins
targeting egfr
antibodies targeting
pharmaceutical compositions
egfr
Prior art date
Application number
MX2023001556A
Other languages
English (en)
Inventor
Christopher Ryan Morgan
Asya Grinberg
Zong Sean Juo
Katia Liharska
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2023001556A publication Critical patent/MX2023001556A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se describen proteínas con dominios variables de la cadena ligera y cadena pesada de anticuerpos que pueden aparearse para formar un sitio de unión a antígeno que se dirige a EGFR en una célula, composiciones farmacéuticas que comprenden dichas proteínas, y métodos terapéuticos que usan dichas proteínas y composiciones farmacéuticas, incluyendo para el tratamiento del cáncer.
MX2023001556A 2020-08-05 2021-08-05 Anticuerpos que se dirigen a egfr y uso de los mismos. MX2023001556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063061507P 2020-08-05 2020-08-05
PCT/US2021/044688 WO2022031935A1 (en) 2020-08-05 2021-08-05 Antibodies targeting egfr and use thereof

Publications (1)

Publication Number Publication Date
MX2023001556A true MX2023001556A (es) 2023-03-08

Family

ID=77520815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001556A MX2023001556A (es) 2020-08-05 2021-08-05 Anticuerpos que se dirigen a egfr y uso de los mismos.

Country Status (11)

Country Link
US (1) US20230279121A1 (es)
EP (1) EP4192874A1 (es)
JP (1) JP2023536627A (es)
KR (1) KR20230042753A (es)
CN (1) CN116547302A (es)
AU (1) AU2021320253A1 (es)
BR (1) BR112023002150A2 (es)
CA (1) CA3188204A1 (es)
IL (1) IL300246A (es)
MX (1) MX2023001556A (es)
WO (1) WO2022031935A1 (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
JP2004500095A (ja) 2000-02-24 2004-01-08 エクサイト　セラピーズ，　インコーポレイテッド 細胞の同時の刺激および濃縮
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
DK2578685T3 (da) 2005-08-23 2019-06-03 Univ Pennsylvania Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US8628773B2 (en) * 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
ES2641877T3 (es) 2011-05-06 2017-11-14 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Inmunotoxina recombinante dirigida a mesotelina
NZ630563A (en) 2012-09-27 2017-04-28 Merus Nv Bispecific igg antibodies as t cell engagers
ES2800630T3 (es) 2013-03-12 2021-01-04 Molecular Templates Inc Proteínas citotóxicas que comprenden regiones de unión de reconocimiento celular y regiones de la subunidad A de la toxina Shiga para la eliminación selectiva de tipos de células específicas
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US11028143B2 (en) 2014-01-21 2021-06-08 Novartis Ag Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
EP3134434A4 (en) 2014-04-25 2017-10-25 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
CN115920030A (zh) 2015-12-09 2023-04-07 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d

Also Published As

Publication number Publication date
JP2023536627A (ja) 2023-08-28
WO2022031935A1 (en) 2022-02-10
EP4192874A1 (en) 2023-06-14
CA3188204A1 (en) 2022-02-10
CN116547302A (zh) 2023-08-04
KR20230042753A (ko) 2023-03-29
IL300246A (en) 2023-03-01
BR112023002150A2 (pt) 2023-05-02
US20230279121A1 (en) 2023-09-07
AU2021320253A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2020008336A (es) Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
MX2020008683A (es) Dominios variables de anticuerpo que se dirigen a cd33 y sus usos.
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
MX2022004291A (es) Anticuerpos dirigidos a tirosina cinasa 3 relacionada con fms (flt3) y uso de los mismos.
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
EA202190181A1 (ru) Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2022013882A (es) Anticuerpos dirigidos contra el miembro a de la familia de dominios de lectina tipo c 12 (clec12a) y uso de los mismos.
MX2021001516A (es) Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores.
MX2021000439A (es) Anticuerpos de antigeno anti-tf humanizado.
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
ZA202008095B (en) Humanized antibodies against psma
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2023001556A (es) Anticuerpos que se dirigen a egfr y uso de los mismos.
AR127897A1 (es) Anticuerpos dirigidos a 5t4 y usos de estos
CL2022002569A1 (es) Dominios variables de anticuerpos dirigidos al receptor nkg2d
EA202091688A1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака
AU2022361653A1 (en) Cancer therapy targeting nkg2a
EA202091738A1 (ru) Способы лечения рака антителами-антагонистами к pd-1